The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 2.00 (0.89%)
Spread: 1.50 (0.662%)
Open: 228.00
High: 228.50
Low: 224.50
Prev. Close: 225.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Puretech Health proposes $100m capital return

Tue, 19th Mar 2024 09:46

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

PureTech said on Tuesday that the proposed capital return represented approximately 14% of its market capitalisation based on Monday's closing price and noted that it follows a previous announcement that it will receive approximately $293.0m in gross proceeds from its remaining stake in Karuna.

The AIM-listed group said the offer will be launched after the publication of its full-year results in April, subject to market conditions, and will require shareholder approval.

PureTech added that if the full $100.0m was not returned, then it intends to return any remainder following the completion of the offer, by way of a special dividend.

Chief executive Daphne Zohar said: "PureTech's mission is to generate value both for patients and shareholders, and Bristol Myers Squibb's acquisition of our Founded Entity Karuna Therapeutics for $14.0bn is a testament to our execution on both fronts. We directed $18.5m to the founding and development of Karuna, and not only have we created a potential breakthrough treatment that may change the lives of millions of people living with schizophrenia, but we have also been able to generate $1.1bn in cash for PureTech, with potentially more to come. These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years.

"We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50.0m share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline - as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns."

As of 1055 GMT, PureTech shares were up 8.58% at 221.50p.

Reporting by Iain Gilbert at Sharecast.com

More News
21 Oct 2020 20:31

IN BRIEF: PureTech's Akili Reports New Trial Data For EndeavorRx

IN BRIEF: PureTech's Akili Reports New Trial Data For EndeavorRx

Read more
5 Oct 2020 19:23

UK TRADING UPDATE SUMMARY: Staffline Pens New Deal, Extends Tesco Pact

UK TRADING UPDATE SUMMARY: Staffline Pens New Deal, Extends Tesco Pact

Read more
1 Oct 2020 21:23

IN BRIEF: PureTech Health Appoints Biocon Chair Shaw To Board

IN BRIEF: PureTech Health Appoints Biocon Chair Shaw To Board

Read more
23 Sep 2020 19:09

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

Read more
4 Sep 2020 15:42

IN BRIEF: PureTech's Gelesis Presents Plenity Efficacy & Safety Data

IN BRIEF: PureTech's Gelesis Presents Plenity Efficacy & Safety Data

Read more
27 Aug 2020 15:26

Puretech Health Interim Earnings Surge On Contracts, Product Approvals

Puretech Health Interim Earnings Surge On Contracts, Product Approvals

Read more
26 Aug 2020 14:15

IN BRIEF: PureTech Sells 1.3 Million Karuna Shares For USD100 Million

IN BRIEF: PureTech Sells 1.3 Million Karuna Shares For USD100 Million

Read more
25 Aug 2020 15:21

PureTech Health's Affiliate Sonde Buys NeuroLex Laboratories

PureTech Health's Affiliate Sonde Buys NeuroLex Laboratories

Read more
20 Aug 2020 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
30 Jul 2020 18:00

UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends

UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends

Read more
29 Jul 2020 15:00

Liberum raises target price on 'underappreciated' PureTech Health

(Sharecast News) - Analysts at Liberum raised their target price on biotechnology company PureTech Health from 450.0p to 490.0p on Wednesday, stating the firm had made some "underappreciated" progress.

Read more
29 Jul 2020 13:29

Wednesday broker round-up

(Sharecast News) - Sanne: RBC Capital Markets reiterates sector performer with a target price of 600.0p.

Read more
12 Jul 2020 16:51

Sunday share tips: PureTech, Driver Group

(Sharecast News) - The Sunday Times's Sabah Meddings told readers of her 'Inside the City' column to 'buy' shares of PureTech, citing the the drug maker's ingenious 'portfolio' approach and ample pipeline of treatments in various phases of development.

Read more
8 Jul 2020 15:50

IN BRIEF: PureTech's Sonde Launches Virus Safe Voice Sample Health App

IN BRIEF: PureTech's Sonde Launches Virus Safe Voice Sample Health App

Read more
8 Jul 2020 15:13

Peel Hunt says Vor Biopharma cash call validates Puretech Health's model

(Sharecast News) - Analysts at Peel Hunt reiterated their 'Conviction Buy' recommendation for shares of PureTech Health following a $110.0m funding round for its founded entity Vor Biopharma, arguing that the transaction validated its business model.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.